These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Radad K; Gille G; Rausch WD Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188 [TBL] [Abstract][Full Text] [Related]
9. Overview of Parkinson's disease. Lew M Pharmacotherapy; 2007 Dec; 27(12 Pt 2):155S-160S. PubMed ID: 18041935 [TBL] [Abstract][Full Text] [Related]
10. New treatments for the motor symptoms of Parkinson's disease. Vijverman AC; Fox SH Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835 [TBL] [Abstract][Full Text] [Related]
12. Glutamate receptors as therapeutic targets for Parkinson's disease. Johnson KA; Conn PJ; Niswender CM CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565 [TBL] [Abstract][Full Text] [Related]
13. alpha-Synuclein: a therapeutic target for Parkinson's disease? Maguire-Zeiss KA Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530 [TBL] [Abstract][Full Text] [Related]
14. New directions in the drug treatment of Parkinson's disease. Montastruc JL; Rascol O; Senard JM Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311 [TBL] [Abstract][Full Text] [Related]
15. Bee venom for the treatment of Parkinson's disease: How far is it possible? Awad K; Abushouk AI; AbdelKarim AH; Mohammed M; Negida A; Shalash AS Biomed Pharmacother; 2017 Jul; 91():295-302. PubMed ID: 28477460 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapy of Parkinson's disease: current options and new avenues. Simola N; Pinna A; Fenu S Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838 [TBL] [Abstract][Full Text] [Related]
17. Continuous drug delivery in Parkinson's disease. Senek M; Nyholm D CNS Drugs; 2014 Jan; 28(1):19-27. PubMed ID: 24323838 [TBL] [Abstract][Full Text] [Related]
18. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Le WD; Jankovic J Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913 [TBL] [Abstract][Full Text] [Related]
19. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033 [TBL] [Abstract][Full Text] [Related]
20. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Sarkar S; Raymick J; Imam S Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]